Showing results (611-620 of 673) with videos related to

Sort By:
Pageof 68
The Lancet. Haematology|January 27, 2020
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 studyJean-Jacques Kiladjian, Pierre Zachee, Masayuki Hino, et al.
Blood|October 28, 2017
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamideClaire N Harrison, Adam J Mead, Anesh Panchal, et al.
Blood|July 29, 2006
Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformationPeter J Campbell, E Joanna Baxter, Philip A Beer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2022
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and EfficacyClaire N Harrison, Jacqueline S Garcia, Tim C P Somervaille, et al.
Blood|March 23, 2010
The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasmsAmy V Jones, Peter J Campbell, Philip A Beer, et al.
Cancer|April 13, 2016
The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study GroupHolly L Geyer, Bjorn Andreasson, Heidi E Kosiorek, et al.
Cancer Causes & Control : CCC|January 19, 2019
The Be-Well Study: a prospective cohort study of lifestyle and genetic factors to reduce the risk of recurrence and progression of non-muscle-invasive bladder cancerMarilyn L Kwan, Lawrence H Kushi, Kim N Danforth, et al.
Science (New York, N.Y.)|September 26, 2009
Distribution of mid-latitude ground ice on Mars from new impact cratersShane Byrne, Colin M Dundas, Megan R Kennedy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 9, 2015
A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trialA Davidson, A-S Veillard, A Tognela, et al.
Hemasphere|March 25, 2025
Patient and physician perceptions regarding treatment expectations and symptomatology in polycythemia vera: Insights from the Landmark 2.0 global health surveyClaire N Harrison, David M Ross, Laura Maria Fogliatto, et al.
Pageof 68